Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Bristol Myers Squibb might have popularized the concept of using tumor mutational burden to identify patients most likely to benefit from checkpoint inhibitors, but Merck’s ever dominant Keytruda is claiming the first approval based on the biomarker.
The OK for unresectable or metastatic TMB-high solid tumors — defined as 10 mutations per megabase or more — is the second biomarker-based indication for Keytruda that covers tumors that fit the bill regardless of where in the body they originate.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.